CAT

905.1

+0.07%↑

322.5

-1.72%↓

GEV.US

943

+0.92%↑

RTX

178.82

-1.18%↓

215.41

-0.07%↓

CAT

905.1

+0.07%↑

322.5

-1.72%↓

GEV.US

943

+0.92%↑

RTX

178.82

-1.18%↓

215.41

-0.07%↓

CAT

905.1

+0.07%↑

322.5

-1.72%↓

GEV.US

943

+0.92%↑

RTX

178.82

-1.18%↓

215.41

-0.07%↓

CAT

905.1

+0.07%↑

322.5

-1.72%↓

GEV.US

943

+0.92%↑

RTX

178.82

-1.18%↓

215.41

-0.07%↓

CAT

905.1

+0.07%↑

322.5

-1.72%↓

GEV.US

943

+0.92%↑

RTX

178.82

-1.18%↓

215.41

-0.07%↓

Inicio・Lista de Acciones・Ocugen Inc

Ocugen Inc

Abierto

1.28

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.27

Máximo

1.3

Métricas clave
By Trading Economics
Ingresos	-1.5M -19M
Ventas	1.7M 1.5M
BPA	-0.06
Margen de beneficios	-1,250.946
Empleados	116
EBITDA	-987K -17M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+792.97% upside

Dividendos
By Dow Jones
Próximas Ganancias	31 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-162M 464M
Apertura anterior	1.28
Cierre anterior	1.28

Ocugen Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 jun 2026, 19:20 UTC

Principales Movimientos del Mercado

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

7 jun 2026, 23:46 UTC

Charlas de Mercado

Nikkei Likely to Fall After U.S. Tech Selloff -- Market Talk

7 jun 2026, 23:36 UTC

Charlas de Mercado

Oil Prices Rise Amid Escalating Supply Disruption Concerns -- Market Talk

7 jun 2026, 18:00 UTC

Ganancias

Inflation Readings, Oracle Earnings, the SpaceX IPO, and More to Watch This Week -- Barrons.com

6 jun 2026, 12:40 UTC

Adquisiciones, fusiones, absorciones

Correction to Texas Billionaires Article America's Resort -- WSJ

6 jun 2026, 08:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

6 jun 2026, 08:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

6 jun 2026, 04:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

6 jun 2026, 00:14 UTC

Adquisiciones, fusiones, absorciones

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

5 jun 2026, 21:27 UTC

Ganancias

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 jun 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

5 jun 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

5 jun 2026, 20:20 UTC

Adquisiciones, fusiones, absorciones

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 jun 2026, 20:19 UTC

Adquisiciones, fusiones, absorciones

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 jun 2026, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

5 jun 2026, 19:26 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

5 jun 2026, 19:26 UTC

Charlas de Mercado

Hog Futures Tumble to Close Week -- Market Talk

5 jun 2026, 19:10 UTC

Charlas de Mercado

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 jun 2026, 19:03 UTC

Charlas de Mercado

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 jun 2026, 18:59 UTC

Charlas de Mercado

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 jun 2026, 18:47 UTC

Charlas de Mercado

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 jun 2026, 18:34 UTC

Charlas de Mercado

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 jun 2026, 18:33 UTC

Adquisiciones, fusiones, absorciones

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 jun 2026, 17:50 UTC

Ganancias

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 jun 2026, 17:27 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 jun 2026, 16:48 UTC

Adquisiciones, fusiones, absorciones

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 jun 2026, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

5 jun 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

5 jun 2026, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

5 jun 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Ocugen Inc previsión

Precio Objetivo

By TipRanks

792.97% repunte

Estimación a 12 Meses

Media 11.43 USD 792.97%

Máximo 22 USD

Mínimo 7 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ocugen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Ocugen Inc Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.